<DOC>
	<DOCNO>NCT00215891</DOCNO>
	<brief_summary>Objectives : Primary To compare sustained virologic response ( SVR ) PEGIntron plus ribavirin among patient receive 48 week versus 72 week therapy ( define undetectable HCV RNA level 24 week discontinue therapy ) . Secondary - To evaluate safety tolerability PEG Intron combination ribavirin treatment Chronic Hepatitis C ( CHC ) infection patient co-infected Human Immunodeficiency Virus ( HIV ) . - To determine early virologic response patient receive PEGIntron plus ribavirin Treatment Week 24 Study Design : All qualify patient enter treatment phase dose follow : Peginterferon a-2b 1.5mg/kg subcutaneous route weekly plus Ribavirin : - 800 mg ( 400 mg bid ) body weight &lt; 65 kg - 1000 mg ( 400 mg a.m. 600 mg p.m. ) body weight &gt; 65 kg &lt; 85 kg - 1200 mg ( 600 mg bid ) body weight &gt; 85 kg &lt; 105 kg - 1400 mg ( 600 mg a.m. 800 mg p.m. ) body weight &gt; 105 kg At Treatment Week 24 , participant detectable HCV-RNA discontinue treatment follow Post Treatment period 24 week . Participants undetectable HCV-RNA value Treatment Week 24 randomize either : - Group A : additional 24 week previously assign Peginterferon a-2b + Ribavirin therapy , total 48 week treatment . - Group B : additional 48 week previously assign Peginterferon a-2b + Ribavirin therapy , total 72 week treatment . Study Population : 300 HIV infect adult chronic hepatitis C infection treat previously interferon therapy . Dosage Administration : Peginterferon a-2b 1.5mg/kg subcutaneous route weekly plus Ribavirin : - 800 mg ( 400 mg bid ) body weight &lt; 65 kg - 1000 mg ( 400 mg a.m. 600 mg p.m. ) body weight &gt; 65 kg &lt; 85 kg - 1200 mg ( 600 mg bid ) body weight &gt; 85 kg &lt; 105 kg - 1400 mg ( 600 mg a.m. 800 mg p.m. ) body weight &gt; 105 kg Efficacy Evaluations : Laboratory analysis , liver biopsy , quality life assessment , change Peginterferona-2b Ribavirin dosage obtain . Safety Evaluations : - Assessment laboratory evaluation - vital sign - incidence severity adverse experience - dose adjustment - premature withdrawal safety reason - progression disease measure HCV viral load - AIDS define event</brief_summary>
	<brief_title>PEG-Interferon a-2b + Ribavirin Treatment Chronic HRN 005 Hepatitis C Infection HIV-Infected Persons Not Previously Treated With Interferon</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>5.2 Inclusion Criteria To eligible trial , patient must documentation follow : 5.2.1 Written inform consent specific protocol obtain prior screen willingness participate comply study . 5.2.2 Male female patient &gt; 18 year age . 5.2.3 Detectable plasma HCVRNA RTPCR assay ( bDNA ) . 5.2.4 HCV genotype result must available screening ( historical determination genotype acceptable ) . 5.2.5 Evidence HIV infection ( reactive HIV antibody Western blot confirmation ) . 5.2.6 Compensated liver disease follow laboratory parameter screen ( result within 1 month screen ) : Hemoglobin value ³ 11 gm/dL WBC ³ 3,000/mm3 Neutrophil count ³1,250/mm3 Platelets ³ 70,000/mm3 Prothrombin time £ 3 second prolonged compare control , equivalent INR ratio Bilirubin within 20 % upper limit normal ( unless nonhepatitis related factor Gilbert 's disease use indinivir explains indirect bilirubin rise ) . Albumin ³ 3.0 g/dL Serum creatinine £ 1.4 mg/dL Fasting blood sugar £ 115 mg/dL nondiabetic patient Hemoglobin A1C £ 8.5 % diabetic patient ( whether medication and/or diet control ) 5.2.7 Thyroid Stimulating Hormone ( TSH ) within normal limit thyroid disease clinical control ( within 3 month screen ) 5.2.8 Alphafetoprotein ( AFP ) value within normal limit obtain within prior year . For patient result upper limit normal &lt; 100 ng/mL follow require : Alphafetoprotein value &lt; 100 ng/mL obtain within 3 month prior entry AND Ultrasound obtain within 3 month prior entry negative evidence hepatocellular carcinoma . 5.2.9 CD4 T cell count HIV RNA level ( RTPCR ) within 1 month screening : CD4 &lt; 100 Eligible HIV RNA &lt; 25,000 RTPCR CD4 &gt; 100 Eligible HIV RNA level RTPCR 5.2.10 Stable antiretroviral regimen FDAapproved agent least 4 week prior baseline . 5.2.11 Reconfirmation documentation sexually active female patient childbearing potential practicing adequate contraception ( intrauterine device , oral contraceptive , progesterone implant rod [ Norplant ] , medroxyprogesterone acetate [ DepoProvera ] , surgical sterilization , barrier method [ diaphragm + spermicide ] , monogamous relationship male partner vasectomy use condom + spermicide ) treatment period 6 month discontinuation therapy . Female patient must breast feed treatment period 6 month discontinuation therapy . A urine pregnancy test obtain entry prior initiation treatment must negative . 5.2.12 Reconfirmation documentation sexually active male patient practice acceptable method contraception ( vasectomy , use condom + spermicide , monogamous relationship female partner practice acceptable method contraception ) treatment period 6 month discontinuation therapy . 5.2.13 Anyone high risk coronary artery disease stress test perform prior entry . This would include , limited , patient age 55 history ischemia significant history hypertension , diabetes mellitus , obesity , smoke and/or strong family history coronary artery disease . Patients evidence ischemia rest stress EKG , history arrhythmia , angina myocardial infarction within 12 month must exclude . 5.2.14 Although recommend , liver biopsy require study entry . However , liver biopsy obtain , within three year initial screen visit , pathology report collect study data . 5.3 Exclusion Criteria Patients meeting follow criterion eligible trial : 5.3.1 Inability unwillingness provide write informed consent specific protocol unwillingness participate comply study . 5.3.2 Previous therapy interferon alfa . 5.3.3 Women ongoing pregnancy breastfeeding . 5.3.4 Male partner woman pregnant . 5.3.5 Hypersensitivity interferon ribavirin . 5.3.6 Evidence advance liver disease history presence ascites , bleed varix , spontaneous encephalopathy . 5.3.7 Any cause chronic liver disease chronic hepatitis C. 5.3.8 Hemoglobinopathies ( e.g. , Thalassemia ) cause hemolytic anemia . 5.3.9 Any known preexisting medical condition could interfere patient ’ participation protocol include : CNS trauma active seizure disorder require medication ; poorly control diabetes mellitus ; serious pulmonary disease ; immunologicallymediated disease ; gout ; medical condition requiring , likely require course study , chronic systemic administration steroid . 5.3.10 Patients evidence ischemia upon stress test ( require patient risk history coronary artery disease , ECG evidence ischemia , arrhythmia , cardiac failure , coronary surgery , uncontrolled hypertension , angina myocardial infarction within 12 month ) . 5.3.11 Active acute HIVrelated opportunistic infection . 5.3.12 Evidence severe retinopathy ( e.g . CMV retinitis , macular degeneration ) 5.3.13 History major organ transplantation exist functional graft ( include Bone Marrow Transplants ) 5.3.14 History systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) £6 month prior first dose study drug expectation treatment need time study . 5.3.15 Concomitant medication , rifampin/rifampicin , rifabutin , pyrazinamide , isoniazid , ganciclovir , thalidomide , oxymetholone ( Anadrolâ ) , immunomodulatory treatment ( include supraphysiologic dos steroid ) . 5.3.16 Coadministration didanosine ( DDI , dideoxyadenosine 5 ’ triphosphate ) ribavirin recommend . 5.3.17 Evidence alcohol and/or drug abuse within one year entry . Patients methadone program exclude . 5.3.18 Inability abstain alcohol throughout entire course treatment followup . 5.3.19 History severe psychiatric disease , especially depression . Severe psychiatric disease define treatment antidepressant medication major tranquilizer therapeutic dos major depression psychosis , respectively , least 3 month previous time history follow : suicidal attempt , hospitalization psychiatric disease , period disability due psychiatric disease . 5.3.20 History evidence severe illness condition would make patient , opinion investigator , unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>